ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France. Show more

Location: 7-11 boulevard Haussmann, Paris, 75009, France | Website: https://www.abivax.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

525.6M

52 Wk Range

$4.77 - $14.16

Previous Close

$8.30

Open

$8.21

Volume

438,656

Day Range

$8.05 - $8.52

Enterprise Value

488.1M

Cash

103.6M

Avg Qtr Burn

-38.15M

Insider Ownership

0.00%

Institutional Own.

50.19%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date